AzTrials
AzTrials

Sarcoma, Soft TissuePhase 2NCT02367651

Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

A Phase 2 study testing Pazopanib 800 mg in people with Sarcoma, Soft Tissue, run by GlaxoSmithKline.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Pazopanib monotherapy is approved by the Food and Drug Administration (FDA), European Medicines Agency, and other regulatory authorities worldwide for the treatment of patients with advanced renal cell carcinoma and patients with advanced soft tissue sarcoma (STS) who received prior chemotherapy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Sarcoma, Soft Tissue
What is being tested?
Pazopanib 800 mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
0 participants
Where
No sites listed yet
Study dates
Jun 2015to May 2018
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Provide signed written informed consent before performing study-specific procedures or assessments and are willing to comply with treatment and follow-up.
  • Age >= 18 years
  • Have a local histopathological diagnosis of one the following STS tumor types based on World Health Organization (WHO) 2013 classification. Fibroblastic (adult fibrosarcoma, myxofibrosarcoma, sclerosing epithelioid fibrosarcoma, malignant solitary fibrous tumors), Leiomyosarcoma , Vascular (epithelioid haemangioendothelioma, angiosarcoma), Skeletal muscle (pleomorphic and alveolar rhabdomyosarcoma only), Malignant peripheral nerve sheath tumors, Malignant glomus tumors, Alveolar soft part sarcoma, Uncertain differentiation (synovial, epithelioid, clear cell, desmoplastic small round cell, extra-renal rhabdoid, malignant mesenchymoma, perivascular epithelioid cell tumor [PEComa], intimal sarcoma), Undifferentiated soft tissue sarcomas (undifferentiated pleomorphic sarcoma or undifferentiated not otherwise specified), Other types of sarcoma not in listed exclusion criteria (contact medical monitor in case of unclear eligibility of a given subtype)
  • Completed 4 to 6 cycles of first-line anthracycline-based chemotherapy for metastatic disease without disease progression.
  • Note: Subjects must have no evidence of radiological progression as confirmed by Computed Tomography (CT)/ Magnetic Resonance Imaging (MRI) within 4 weeks before randomization and no signs of clinical progression before randomization.
  • The date of study randomization must be 3 to 8 weeks following the last dose of chemotherapy. All chemotherapy-related side effects (except alopecia) must have resolved to grade 1 or better.
Show all 14Show fewer
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Able to swallow and retain oral tablets.
  • Adequate baseline organ function
  • Baseline Left Ventricular Ejection Fraction (LVEF) above lower limit of normal (LLN) based on institution's normal range.
  • Corrected QT interval (QTc) <450 milliseconds (msec) or QTc <480 msec for subjects with bundle branch block. For subject eligibility and withdrawal, Bazett's QT correction formula (QTcB) will be used. The QTc should be based on single or averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period.
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first dose of study treatment and agree to use effective contraception, as defined in Study Protocol during the study and for 14 days following the last dose of study treatment.
  • Note: Female subjects who are lactating must discontinue nursing before the first dose of study treatment and refrain from nursing from the first dose until 14 days following the last dose of study treatment.
  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Who cannot join

  • Prior malignancy. Note: Subjects who have had another malignancy and have been disease-free for 3 years or more, or subjects with a history of completely resected non-melanoma skin carcinoma or successfully treated in situ carcinoma are eligible.
  • Any of the following tumor types: Adipocytic sarcoma (all subtypes) , All rhabdomyosarcoma that are NOT alveolar or pleomorphic, Chondrosarcoma, Osteosarcoma, Ewing tumors / primitive neuroectodermal tumor (PNET), Gastro-intestinal stromal tumors (GIST), Dermofibromatosis sarcoma protuberans, Inflammatory myofibroblastic sarcoma, Malignant mesothelioma, Mixed mesodermal tumors of the uterus (carcinosarcoma), Subjects with low grade histology (French Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade 1 or those with incomplete grading information FNCLCC grade X)
  • Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding within 28 days before beginning study treatment.
  • Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: Malabsorption syndrome, Major resection of the stomach or small bowel
  • History of any one or more of the following cardiovascular conditions within the past 6 months: Cardiac angioplasty or stenting, Myocardial infarction, Unstable angina, Coronary artery bypass graft surgery, Symptomatic peripheral vascular disease, Class III or IV congestive heart failure (CHF), as defined by the New York Heart Association (NYHA)
  • Poorly controlled hypertension (defined as systolic blood pressure [SBP] >=140 millimeters of mercury (mmHg) or diastolic blood pressure [DBP] >= 90 mmHg)
Show all 22Show fewer
  • History of cerebrovascular accident (CVA), transient ischemic attack (TIA), pulmonary embolism (PE), or deep venous thrombosis (DVT) within the past 6 months unless therapeutically coagulated for at least 6 weeks.
  • Major surgery or trauma within 28 days before the first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery).
  • Evidence of active bleeding or bleeding diathesis.
  • Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage.
  • Note: Lesions infiltrating major pulmonary vessels (contiguous tumor and vessels) are excluded; however, the presence of a tumor that is touching but not infiltrating (abutting) the vessel is acceptable (CT with contrast is strongly recommended to evaluate such lesions).
  • Recent hemoptysis (>= 1/2 teaspoon or 2.5 milliliters of red blood) within 8 weeks of the first dose of study drug.
  • Any of the following hepatic or biliary conditions:
  • Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months before the first dose of study treatment. Exception: subject can be enrolled if hepatitis C Ribonucleic acid (RNA) is negative.
  • Presence of another active liver or biliary disease. Exceptions: subject can be enrolled in case of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per investigator assessment.
  • Note: Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, persistent jaundice, or cirrhosis.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures.
  • A positive pre-study alcohol screen.
  • A positive test for human immunodeficiency virus (HIV) antibody.
  • Unable or unwilling to discontinue use of prohibited medications for at least 14 days or 5 half-lives of a drug (whichever is longer) before the first dose of study treatment and for the duration of the study.
  • Treatment with any of the following anti-cancer therapies: Radiation therapy, surgery or tumor embolization within 14 days before the first dose or pazopanib OR chemotherapy, immunotherapy, biologic therapy (including prior pazopanib or other Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor Receptor [PDGFR], or Cytokine Receptor [c-Kit] inhibitor), investigational therapy, or hormonal therapy within 14 days or 5 half-lives of a drug (whichever is longer) before the first dose of pazopanib.
  • A known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or excipients that contraindicate their participation.

About this study

Official title: A Randomized, Double-blind, Placebo-controlled Phase II Study of Pazopanib Versus Placebo as Maintenance Therapy for Patients Who Have Not Progressed After First-line Chemotherapy for Advanced Soft Tissue Sarcoma (STS)

Pazopanib monotherapy is approved by the Food and Drug Administration (FDA), European Medicines Agency, and other regulatory authorities worldwide for the treatment of patients with advanced renal cell carcinoma and patients with advanced soft tissue sarcoma (STS) who received prior chemotherapy. Based on the improved progression-free survival and sustained responses observed in a pivotal Phase 3, randomized, placebo-controlled study, it is hypothesized that pazopanib may have a role in a maintenance setting for STS in maintaining the initial response to chemotherapy and delaying the need for further treatment at relapse and its associated toxicity and impact on health-related quality-of-life. This Phase 2, randomized, double-blind, placebo-controlled study will evaluate maintenance therapy with pazopanib versus placebo in subjects with advanced or metastatic STS who have not progressed after 4 to 6 cycles of first-line anthracycline-based chemotherapy. Approximately 188 eligible subjects will be randomized in a 1:1 ratio to treatment with pazopanib 800 milligrams (mg) daily or placebo. Study completion will be the point at which 70% of randomized subjects have died. Once a subject has objective evidence of disease progression, the subject will be managed as per standard practice by their physician. Subjects will continue to be followed for second progression, health related quality of life, survival until study completion, withdrawal of consent, or early termination of the study.

Being tested
Pazopanib 800 mg, Placebo
Keywords
Soft tissue sarcoma, Pazopanib, Tyrosine kinase inhibitor
Medical subject headings
Sarcoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pazopanib 800 mgDrug

    Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib

  • PlaceboDrug

    Tablets matching the 200 mg and 400 mg pazopanib tablets

Study groups in NCT02367651
Study groupRoleWhat they receive
PazopanibExperimentalSubjects will receive pazopanib 800 mg once daily during each 28-day treatment period until disease progression, unacceptable adverse event (AE)/serious adverse event (SAE), death or withdrawal of consent
Receives: Drug: Pazopanib 800 mg
PlaceboPlacebo comparatorSubjects will receive placebo once daily during each 28-day treatment period until disease progression, unacceptable AE/SAE, death or withdrawal of consent
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-free survival (PFS)

    PFS is defined as time from randomization to development of disease progression or death due to any cause. Disease progression will be evaluated based on investigators' radiologic assessments by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1

    Measured: At Day 57 and every 8 weeks thereafter until disease progression or death (assessed up to 2 years)

Secondary outcomes (10)

  1. Overall survival (OS)

    OS is defined as time from randomization to death due to any cause.

    Measured: At Day 57, then every 8 weeks until disease progression, and every 3 months thereafter until death (assessed up to 2 years)

  2. Disease control rate (DCR)

    DCR is defined as percentage of complete response + partial response + stable disease at 4 months after randomization based on RECIST version 1.1.

    Measured: At 4 months after randomization

  3. Safety and tolerability as assessed by physical examination findings

    A brief physical examination will include height (baseline only), body weight and evaluation of the subject's medical conditions

    Measured: From Day 1 up to end of treatment (assessed up to 2 years)

  4. Safety and tolerability as assessed by temperature measurement

    Measured: From Day 1 up to end of treatment (assessed up to 2 years)

  5. Safety and tolerability as assessed by systolic and diastolic blood pressure measurement

    Measured: From Day 1 up to end of treatment (assessed up to 2 years)

  6. Safety and tolerability as assessed by pulse rate measurement

    Measured: From Day 1 up to end of treatment (assessed up to 2 years)

  7. Safety and tolerability as assessed by composite of clinical laboratory tests

    Clinical laboratory tests will include chemistry and hematology parameters

    Measured: From Day 1 up to end of treatment (assessed up to 2 years)

  8. Safety and tolerability as assessed by cardiac assessments

    Cardiac assessments will include twelve-lead electrocardiogram (ECG), echocardiogram (ECHO) or multigated angiogram (MUGA) assessments

    Measured: From Day 1 up to end of treatment (assessed up to 2 years)

  9. Safety and tolerability as assessed by number of subjects with adverse event

    Measured: From Day 1 up to end of treatment (assessed up to 2 years)

  10. Time to worsening of dyspnea or pain scores as measured by the MD Anderson Symptom Inventory (MDASI) questionnaire

    The MDASI is a 19-item general cancer questionnaire asking subjects to rate symptoms at their worst on a scale of 0-10, including pain and shortness of breath as items. Time to symptom deterioration is defined as worsening in tumour pain score or dyspnea score of 2 points or more from baseline, confirmed by at least one additional weekly measure within a four week period.

    Measured: Weekly from baseline up to week 48

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Feb 2015 (estimated)
  2. Study startJun 2015
  3. Primary completionMay 2018 (estimated)
  4. Study completionMay 2018 (estimated)

Why it stopped: Study cancelled: Withdrawn before enrollment of any participants

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02367651
Sponsor's protocol ID
201187
Status last verified
Oct 2016
First submitted
12 Feb 2015
Last updated
12 Oct 2016
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Pazopanib 800 mg in people with Sarcoma, Soft Tissue, run by GlaxoSmithKline.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 12 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-free survival (PFS) (time frame: At Day 57 and every 8 weeks thereafter until disease progression or death (assessed up to 2 years)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02367651.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2016.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in